



1



2



3



4

The Biomarker Playbook: Understanding the Markers That Shape Access to Therapy

Sara Rentzel, CPhT, CPhT
American Oncology Network (AON)

The slide has a dark blue background with a faint image of a person's face. The title is in white text. The speaker's name and affiliation are listed below. The logo for '2026 NCOA INTERNATIONAL SPRING FORUM' is in the bottom right corner.

5

How to Claim Your CE Credit

For CE credit, please visit:
<https://www.lecturepanda.com/r/2026NCOASpringForum>

- Credit requirements must be completed within 60 days of the program activity date.
- Upon completion, credit will be transmitted electronically to ACPE.
- All transmitted credit will be viewable in your CPE Monitor profile within 24 hours.
- CE codes will be displayed at the end of the presentation and will not be redistributed after this presentation.


A square QR code is located on the left side of the slide. The background features a faint image of a person's face. The logo for '2026 NCOA INTERNATIONAL SPRING FORUM' is in the bottom right corner.

6

DISCLOSURES 2026 NCI NATIONAL BIOMARKER SPRING FORUM

There are no relevant conflicts of interest to disclose for this presentation for the following planners and speakers of this CE activity:


- Sara Rentzel, CPhT, COPhT
- Taryn Newsome, CPhT
- Tahsin Imam, PharmD



7

OBJECTIVES 2026 NCI NATIONAL BIOMARKER SPRING FORUM

1. Describe the role of biomarker testing in oncology treatment selection and its growing influence on payer authorization requirements.
2. Identify commonly referenced oncology biomarkers and locate corresponding results within pathology reports and electronic medical records.
3. Apply biomarker documentation requirements to support prior authorization and treatment coordination.
4. Recognize biomarker-related documentation gaps that may contribute to prior authorization delays or denials and impact treatment coordination.



8

Agenda


- Biomarkers & Access to Therapy
- Locating Biomarker Information
- Workflow & Documentation
- Challenges & Delays
- Case-Based Discussion
- Key Takeaways




9



10




11




12



13




14



15

Common Challenges in Biomarker Documentation


- Report not uploaded or difficult to locate
- Information buried in scanned documents
- Missing or incomplete reports
- Mismatch between therapy and documented biomarkers



16


What Leads to Delays in Therapy Initiation

- Missing biomarker documentation
- Incorrect or incomplete report submitted
- Timing mismatch (test vs therapy order)
- Communication gaps across the care team



17


Case-Based Discussion



18

Case 1: What's Missing


Patient: <ul style="list-style-type: none">• Metastatic non-small cell lung cancer (NSCLC)	Chart includes: <ul style="list-style-type: none">• Progress note referencing EGFR mutation• Scanned pathology report
Therapy ordered: <ul style="list-style-type: none">• osimertinib	
Prior authorization denied: <ul style="list-style-type: none">• "Biomarker confirmation not provided"	



19

Case 2: Timing Matters


Patient: Newly diagnosed ALK+NSCLC	Plan: Start therapy this week!
Therapy ordered: alectinib	
<ul style="list-style-type: none">• Biomarker testing has been ordered• Results are still pending	



20

Case 3: Ready to Compound?

Patient: Metastatic colorectal cancer	Chart includes: <ul style="list-style-type: none">• Pathology report• No clear documentation of KRAS/NRAS status
Therapy ordered: cetuximab	
<ul style="list-style-type: none">• Scheduled for infusion tomorrow	




21

QUESTION & ANSWER 2026 NCODA INTERNATIONAL SPRING FORUM

The Biomarker Playbook: Understanding the Markers That Shape Access to Therapy

Sara Rentzel, CPhT, COPhT
American Oncology Network (AON)


Jerry Mitchell, MD, MBA
Foundation Medicine



22

SUMMARY 2026 NCODA INTERNATIONAL SPRING FORUM

- Biomarkers are essential for determining therapy eligibility and access
- Payers require clear biomarker documentation for approval
- Results are often located in pathology or molecular testing reports
- Missing, incomplete, or mismatched documentation can delay therapy
- Pharmacy technicians play a critical role in locating, verifying, and submitting biomarker information




23

QUESTION & ANSWER 2026 NCODA INTERNATIONAL SPRING FORUM


The Biomarker Playbook: Understanding the Markers That Shape Access to Therapy

Sara Rentzel, CPhT, COPhT
American Oncology Network

Jerry Mitchell, MD, MBA
Foundation Medicine



24



25



26
